Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
Terminated
This is a Phase IIb/III randomized, double-blind, placebo-controlled study to compare the efficacy and safety of first-line therapy combined with TG4010 or placebo in stage IV non-small cell lung cancer (NSCLC). TG4010 is a suspension of recombinant Modified Vaccinia virus strain Ankara (MVA strain) carrying coding sequences for human MUC1 antigen and human interleukin-2 (IL2). TG4010 has been developed for use as an immunotherapy in cancer patients whose tumors express the MUC1 antigen. TG401... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2017
Locations: Massachusetts General Hospital, Cambridge, Maryland +1 locations
Conditions: Non-Small-Cell Lung Carcinoma
Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Exisulind may make tumor cells more sensitive to chemotherapy. Combining chemotherapy with exisulind may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy with exisulind in treating patients who have extensive-stage small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2016
Locations: Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland +1 locations
Conditions: Lung Cancer
EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202)
Completed
Purpose of this study: There is some evidence that the best treatment for head and neck cancer involves a combination of radiation therapy and chemotherapy. Radiation therapy is a form of cancer treatment using high energy x-rays. Chemotherapy is a form of cancer treatment that uses special medications. This study uses two chemotherapy drugs (Taxol and Carboplatin), which are FDA approved for treating head and neck cancers. This treatment combination has been associated with difficulty, pain, o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2016
Locations: University of Maryland, Baltimore, Maryland
Conditions: Head and Neck Cancer
Ixabepilone + Carboplatin Metastatic Breast Cancer
Completed
Ixabepilone adds significantly to the antitumor effectiveness of capecitabine in both ER+ and triple negative breast cancer. Ixabepilone has substantial antitumor activity in taxane-refractory patients and novel combinations are needed in this poor prognosis population. Carboplatin in combination with gemcitabine or paclitaxel has activity in metastatic breast cancer (MBC); there is also demonstrated activity of the gemcitabine/carboplatin combination in the ER+ versus triple negative subsets. A... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2016
Locations: Alliance Hematology Oncology, P.A., Westminster, Maryland
Conditions: Metastatic Breast Cancer
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
Completed
The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/15/2016
Locations: Maryland Oncology Hematology, PA, Columbia, Maryland +1 locations
Conditions: Metastatic Breast Cancer
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Completed
This trial will examine the combination of sunitinib plus paclitaxel and carboplatin as neoadjuvant treatment for locally advanced breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/02/2016
Locations: Center for Cancer and Blood Disorders, Bethesda, Maryland +1 locations
Conditions: Breast Cancer
Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer
Completed
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Oth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2016
Locations: Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland +2 locations
Conditions: Lung Cancer
Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether giving chemotherapy before combined chemotherapy and radiation therapy is more effective than combined chemotherapy and radiation therapy alone in treating patients with non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin and pacl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2016
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Conditions: Lung Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and giving them before and with radiation therapy may be an effective treatment for limited-stage small cell lung cancer. PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus radiation therapy in treating patients who have limited-stage small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2016
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Conditions: Lung Cancer
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Completed
The Phase I portion of this protocol will determine the best phase II dose and schedule of obatoclax with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. The Phase II portion will evaluate the response rate to this regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2016
Locations: Center for Cancer and Blood Disorders, Bethesda, Maryland
Conditions: Extensive-stage Small Cell Lung Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and radiation therapy in treating patients who have limited-stage small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/15/2016
Locations: Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Conditions: Lung Cancer
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
Completed
The purpose of this project is to see if weekly carboplatin compared with phenoxodiol in combination with weekly carboplatin, is effective against late stage ovarian cancer and to see what, if any, side-effects of treatment may result.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/13/2016
Locations: Greater Baltimore Medical Centre, Baltimore, Maryland
Conditions: Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer